Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

Archive du jour : février 23, 2021

Le ministre de la Santé et des Affaires sociales, Chen Shih-chung, a annoncé le 22 février la prolongation des mesures de prévention contre le Covid-19. © Aimable crédit du CECC 0

[Taiwan] Covid-19 : Taiwan prolonge ses mesures de prévention

Malgré l’absence de nouveaux cas de Covid-19 à Taiwan ces derniers jours, la situation mondiale reste préoccupante, raison pour laquelle la plupart des mesures de prévention adoptées ici pour l’hiver vont rester en place, a expliqué le 22 février le ministre de la Santé et des Affaires sociales, Chen Shih-chung [陳時中]. Il s’exprimait lors d’une conférence de presse du Quartier général de lutte épidémique (CECC), à Taipei.

COVID-19 inactivated vaccine products are packaged at a packaging plant of the Beijing Biological Products Institute Co Ltd in Beijing, capital of China, Dec 25, 2020. © Xinhua 0

[Chine] Chinese jabs ‘effective for virus variants’

China’s COVID-19 vaccines are effective against the two major variants of the novel coronavirus that have been imported, but sustained efforts are still needed to prevent other strains from entering, the Chinese Center for Disease Control and Prevention said.

0

[Thaïlande] Thailand announces plans for human trials after developing its second COVID-19 vaccine

Following the production of its second domestically developed COVID-19 vaccine, Thailand is all set to commence its human trials from as early as April this year.
The vaccine which was developed by Chulalongkorn University showed promising results in prior trials with mice and monkeys. The University’s Centre of Excellence in Vaccine Research and Development is utilizing new mRNA technology and its clinical testing on transgenic mice showed that the vaccine was able to prevent clinical symptoms and viremia after two shots. The university is looking to enroll 72 participants in the first phase of the human trials and subsequently increase the number to 300-600 participants in the second phase. The university has also begun research on a second-generation vaccine that will help grant additional protection to its citizens against the UK and South African variants of the COVID-19 virus.